Arvind Hundal chief business officer at Zealand
This article was originally published in Scrip
Zealand Pharma, a Danish biopharmaceutical company developing innovative peptide drugs, has appointed Dr Arvind Hundal senior vice-president and chief business officer. Dr Hundal joined Zealand Pharma in August 2009 as vice-president of business development. Prior to that, she served as business development director for 7TM Pharma.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.